Pulmonx (LUNG) Preferred Stock Liabilities (2019 - 2020)
Pulmonx (LUNG) posted quarterly Preferred Stock Liabilities of $207.6 million for Q3 2020, up 1.1% year-over-year from $205.3 million in Q4 2019, and little changed quarter-over-quarter from $207.6 million in Q2 2020.
Pulmonx (LUNG) Preferred Stock Liabilities (2019 - 2020) Analysis & Trends
Pulmonx (LUNG) has reported Preferred Stock Liabilities for 2 consecutive years, with $207.6 million the latest figure, recorded in Q3 2020.
- In Q3 2020, Preferred Stock Liabilities rose 1.1% year-over-year to $207.6 million; the TTM figure through Sep 2020 stood at $207.6 million (up 1.1% YoY), while the FY2019 annual figure was $205.3 million, up 46.11% from the prior year.
- Preferred Stock Liabilities steadied at $207.6 million in Q3 2020 per LUNG's latest filing, from $207.6 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $207.6 million in Q1 2020 and bottomed at $205.3 million in Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.24 Bn | 193.64 Bn | 7.27 Bn | - |
| 2 | Stryker | 128.63 Bn | 125.15 Bn | 4.50 Bn | - |
| 3 | Medtronic | 119.19 Bn | 109.97 Bn | 6.41 Bn | - |
| 4 | Boston Scientific | 73.51 Bn | 72.97 Bn | 3.85 Bn | - |
| 5 | Edwards Lifesciences | 52.11 Bn | 47.85 Bn | 1.35 Bn | - |
| 6 | Dexcom | 34.64 Bn | 32.70 Bn | 830.00 Mn | - |
| 7 | GE HealthCare Technologies | 34.01 Bn | 31.90 Bn | 2.18 Bn | - |
| 8 | Koninklijke Philips | 26.40 Bn | 23.08 Bn | 4.55 Bn | - |
| 9 | Steris | 23.14 Bn | 22.65 Bn | 684.20 Mn | - |
| 10 | Pulmonx | 94.56 Mn | 24.81 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 207.60 Mn |
| Jun 30, 2020 | 207.60 Mn |
| Mar 31, 2020 | 207.60 Mn |
| Dec 31, 2019 | 205.34 Mn |
| Sep 30, 2019 | 205.34 Mn |